HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS

Brain tumors are the leading cause of cancer-related death in children. We report interim results of an ongoing multi-institutional phase 2 trial (NCT04049669) of the IDO pathway-inhibitor indoximod utilized in a chemo-immunotherapy regimen for patients 3-21 years of age with either recurrent malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Theodore S, Pacholczyk, Rafal, Aguilera, Dolly, Berrong, Zuzana, Castellino, Robert C, Chi, Susan, Creager, Julianne, Eaton, Bree R, Fangusaro, Jason R, Huang, Chenbin, Hummel, Trent, Ingerski, Lisa, Kennedy, Eugene P, Ring, Eric, Sadek, Ramses F, Satpathy, Sarthak, Schniederjan, Matthew, Thomas, Beena E, Yeo, Kee Kiat, Bhasin, Manoj, MacDonald, Tobey J, Munn, David H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259940/
http://dx.doi.org/10.1093/neuonc/noad073.177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259940/
http://dx.doi.org/10.1093/neuonc/noad073.177

Ejemplares similares